Clinical Value of Iodine-123 Beta-Methyliodophenyl Pentadecanoic Acid (BMIPP) Myocardial Single Photon Emission Computed Tomography for Predicting Cardiac Death among Patients with Chronic Heart Failure

Circulation Journal

Volumn 67, Issue 11, 2003, Pages 918-924

  Sasaki, Ryu ^a   Mitani, Isao ^b   Usui, Takashi ^a   Kitamura, Yutaka ^c   Yoshii, Yuzuru ^d   Ishikawa, Toshiyuki ^b   Uchino, Kazuaki ^b   Takahashi, Nobukazu ^b   Kimura, Kazuo ^b   Umemura, Satoshi ^b  

^a FUJISAWA CITY HOSPITAL   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d Saiseikai Yokohama Nanbu Hospital   (Japan)

Author keywords

Fatty acid metabolism; Heart failure; Nuclear cardiology

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; DIAGNOSTIC VALUE; FATTY ACID METABOLISM; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MEDICINE; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RECIPIENT; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; DEATH; FATTY ACIDS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; IODINE RADIOISOTOPES; IODOBENZENES; MALE; MIDDLE AGED; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; ROC CURVE; SEVERITY OF ILLNESS INDEX; STROKE VOLUME;

EID: 10744219614     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.67.918     Document Type: Article

References (41)

1. Knapp FF Jr, Ambrose KR, Goodman MM. New radioiodinated methyl-branched fatty acid for cardiac studies. Eur J Nucl Med 1986; 12: S39-S44.
2. Fujibayashi Y, Yonekura Y, Takemura Y, Wada K, Matsumoto K, Tamaki N. Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodo-phenyl)-3-(RS)methylpentadecanoic acid (BMIPP), in relation to ATP concentration. J Nucl Med 1990; 31: 1812-1822.
3. Nohara R, Hosokawa R, Okuda K, Ogino M, Fujita M, Tamaki N, et al. Mechanism of myocardial uptake of 1231-BMIPP. Shinzou 1997; 29: 16-21.
4. Kataoka K, Nohara R, Hosokawa R, Hirai T, Okuda K, Chen Li-Guang, et al. Myocardial lipid metabolism in compensated and advanced stage of heart failure: Evaluation by canine pacing model with BMIPP. J Nucl Med 2001; 42: 124-129.
5. Hosokawa R, Nohara R, Fujibayashi Y, Okuda K, Ogino M, Hata T, et al. Myocardial kinetics of iodine-123-BMIPP in canine myocardium after regional ischemia and reperfusion: Implications for clinical SPECT. J Nucl Med 1997; 38: 1857-1863.
6. Chen L, Nohara R, Hirai T, Li X, Kataoka K, Hosokawa R, et al. Effects of exercise training on myocardial fatty acid metabolism in rats with depressd cardiac function induced by transient ischemia. Jpn Circ J 2001; 65: 550-555.
7. Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M, et al. Total body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994; 43: 174-179.
8. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in conscious dog. Circ Res 1998; 83: 969-979.
9. Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: Potential for therapeutic interventions. Heart Fail Rev 2002; 7: 115-130.
10. Tamaki N, Kawamoto M, Yonekura Y, Fujibayashi Y, Takahashi N, Konishi J. Regional metabolic abnormality in relation to perfusion and wall motion in patient with myocardial infarction: Assessment with emission tomography using an iodinated branched fatty acid analog. J Nucl Med 1992; 33: 659-667.
11. Kurata C, Tawarahara K, Taguchi T, Aoshima S, Kobayashi A, Yamazaki N. Myocardial emission computed tomography with iodine-123-labeled beta-methyl-branched fatty acid in patients with hypertrophic cardiomyopathy. J Nucl Med 1992; 33: 6-13.
12. Narita M, Kurihara T, Usami M, Honda M. Is myocardial fatty acid metabolism different between hypertrophic cardiomyopathy and hypertensive hypertrophy? Kakuìgaku 1994; 31: 1465-1476.
13. Hock A, Freundlieb C, Vyska K, Losse B, Erbel R, Feinendgen LE. Myocardial imaging and metabolic studies with (17-1231) iodopentadecanoic acid in patients with idiopathic congestive cardiomyopathy. J Nucl Med 1983; 24: 22-28.
14. Ugolini V, Hansen CL, Kulkami P, Jansen DE, Akers MS, Corbett JR. Abnormal myocardial fatty acid metabolism in dilated cardiomyopathy detected by iodine-123 phenylpentadecanoic acid tomographic imaging. Am J Cardiol 1988; 62: 923-928.
15. Narita M, Kurihara T. Fatty acid metabolism in patient with idiopathic dilated cardiomyopathy: Characteristics and prognosis implications. J Cardiol 1995; 25: 223-231.
16. 123I-BMIPP imaging in patients with congestive heart failure without coronary artery disease. Kakuigaku 1998; 35: 229-237.
17. 123I-BMIPP myocardial scintigraphy for evaluation of the left ventricular function in patients with chronic heart failure. Kakuigaku 1996; 33: 743-751.
18. Yasugi N, Koyanagi S, Ohzono K, Matsumoto T, Sako S, Homma T, et al. Comparative study of dobutamine stress echocardiography and dual single-photon emission computed tomography (thllium-201 and 1-123 BMIPP) for assessing myocardial viability after acute myocardial infarction. Circ J 2002; 66: 1132-1138.
19. Teraguchi M, Ikemoto Y, Kobayashi Y. Effective disopyramide treatment in a boy with mid-ventricular hypertrophic obstructive cardiomyopathy. Circ J 2002; 66: 709-711.
20. 201Tl myocardial single photon emission computed tomography. Jpn Circ J 2001; 65: 769-774.
21. Owa M, Aizawa K, Urasawa N, Ichinose H, Yamamoto K,Karasawa K, et al. Emotional stress-induced 'ampulla cardiomyopathy': Discrepancy between the metabolic and sympathetic innervation imaging performed during the recovery course. Jpn Circ J 2001; 65: 349-352.
22. Nakayama H, Morozumi T, Nanto S, Shimonagata T, Ohara T, Takano Y, et al. Abnormal myocardial free fatty acid utilization deteriorates with morphological changes in the hypertensive heart. Jpn Circ J 2001; 65: 783-787.
23. Otsuka Y, Nakayama S, Fukuchi K, Yasumura Y, Komamura K, Yamagishi M, et al. Clinical significance of iodine- 123-15-(piodophenyl)-3-R,S-methylpentadecanoic acid myocardial scintigraphy in patients with aortic valve disease. Circ J 2002; 66: 41-46.
24. Stevenson LW, Dracup KA, Tillisch JH. Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. Am J Cardiol 1989; 63: 461-464.
25. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure: The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87(Suppl): V-I5-V-16.
26. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
27. Ishi J, Nomura M, Nakamura Y, Naruse H, Mori Y, Ishikawa T, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002; 89: 691-695.
28. Maeda K, Tsukamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587-1593.
29. Schwartz F, Mall G, Zobe H. Determinants of survival in patients with congestive cardiomyopathy: Quantitative morphologic findings and left ventricular hemodynamics. Circulation 1984; 70: 923-928.
30. Keogh AM, Freund J, Baron DW, Hickie JB. Timing of cardiac transplantation in idiopathic cardiomyopathy. Am J Cardiol 1988; 61: 418-422.
31. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83: 778-786.
32. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic cardiomyopathy or to ischemic cardiomyopathy. Am J Cardiol 1987; 59: 634-638.
33. Hofmann T, Meinertz T, Kasper W. Mode of death in idiopathic dilated cardiomyopathy: A multivariate analysis of prognostic determinants. Am Heart J 1988; 116: 1455-1463.
34. Popma JJ, Cigarroa RG, Buja LM, Hillis LD. Diagnostic and prognostic utility of right-sided catheterization and endomyocardial biopsy in idiopathic dilated cardiomyopathy. Am J Cardiol 1989; 63: 955-958.
35. Ikram M, Williamson HG, Won M, Crozier IC, Wells ET. The course of idiopathic dilated cardiomyopathy in New Zealand. Br Heart J 1987; 57: 521-527.
36. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990; 65: 903-908.
37. William G. Prognosis in congestive heart failure: What information can best predict the future? J Nucl Med 1992; 33: 477-479.
38. 123I-BMIPP) in relation to the concentration of the substrates of energy. Kakuigaku 1995; 32: 579-586.
39. Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Duboi C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: Relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999; 33: 759-766.
40. Merlet P, Valette H, Dubois-Rande J, Moyse D, Dove P, Henri M, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33: 471 -477.
41. Mariet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande J, Duval A, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999; 40: 917-923.